Acasti Pharma Inc V.ACST

Primary Symbol: ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc

<< Previous

Bullboard Posts

Next >>

Post by AmandaPearceon May 07, 2021 11:20am

195 Views

Post# 33152254

New To Stockhouse LONG POSITION ACST

Hey everyone, I've been a shareholder of ACST since last October. I've held my position here sturn until the $3 mark. Today someone bought over 250k shares to make our stock price surge. Did some research on Grace Therapeutics they are a golden standard company, this deal is done!!

<< Previous

Bullboard Posts

Next >>

This company starts production at what could be Canada’s next great gold mine